Answers are grounded in this paper and cite their sources.
The quinazoline compound ARS-1620 is a recently discovered, mutant-specific covalent inhibitor of KRASG12C. Route scouting in support of multigram ARS-1620 batches led to a new synthetic approach that relies on metalation of substituted quinazolines at C7. The exquisite selectivity seen in this metalation formed the basis for a scalable route to kilogram quantities of compounds in this family. It also accelerated medicinal chemistry efforts as critical intermediates became readily available in large quantities.
No takes yet. Share an insight, caveat, or question.
Allison et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: